title: Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.
abstract: Best known for their anti-resorptive activity in bone, bisphosphonates (BPs) have generated interest as potential antineoplastic agents given their pleiotropic biological effects which include antiproliferative, antiangiogenic and immune-modulating properties. Clinical studies in multiple malignancies suggest that BPs may be active in the prevention or treatment of cancer. Digestive tract malignancies represent a large and heterogeneous disease group, and the activity of BPs in these cancers has not been extensively studied. Recent data showing that some BPs inhibit human epidermal growth factor receptor (HER) signaling highlight a potential therapeutic opportunity in digestive cancers, many of which have alterations in the HER axis. Herein, we review the available evidence providing a rationale for the repurposing of BPs as a therapeutic adjunct in the treatment of digestive malignancies, especially in HER-driven subgroups.
authors.affiliation: Celina Ang, Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
authors.forename: Celina
authors.initials: C
authors.lastname: Ang
authors.affiliation: Celina Ang, Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
authors.forename: Erin
authors.initials: E
authors.lastname: Doyle
authors.affiliation: Celina Ang, Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
authors.forename: Andrea
authors.initials: A
authors.lastname: Branch
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004067:Digestive System Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Bisphosphonates; Cancer; Gastrointestinal; Hepatobiliary; Human epidermal growth factor
references.citation: J Bone Miner Res. 2000 Aug;15(8):1467-76
references.pmid: 10934645
references.citation: Jpn J Clin Oncol. 2000 Sep;30(9):410-3
references.pmid: 11095140
references.citation: J Pharmacol Exp Ther. 2001 Feb;296(2):235-42
references.pmid: 11160603
references.citation: Mol Pharmacol. 2002 May;61(5):1255-62
references.pmid: 11961144
references.citation: Anticancer Drugs. 2002 Mar;13(3):245-54
references.pmid: 11984068
references.citation: Br J Cancer. 2003 Jun 16;88(12):1971-8
references.pmid: 12799645
references.citation: Anticancer Drugs. 2005 Jan;16(1):87-91
references.pmid: 15613910
references.citation: Med Oncol. 2005;22(2):195-201
references.pmid: 15965284
references.citation: J Hepatol. 2006 Jan;44(1):142-50
references.pmid: 16298452
references.citation: Br J Pharmacol. 2006 Feb;147(4):437-45
references.pmid: 16402039
references.citation: Cell. 2006 Jan 27;124(2):263-6
references.pmid: 16439202
references.citation: Ann N Y Acad Sci. 2006 Apr;1068:367-401
references.pmid: 16831938
references.citation: Med Chem. 2007 Jan;3(1):85-99
references.pmid: 17266628
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: J Immunother. 2007 May-Jun;30(4):370-7
references.pmid: 17457212
references.citation: Cancer Immunol Immunother. 2008 Apr;57(4):531-9
references.pmid: 17764010
references.citation: Med Oncol. 2007;24(2):227-30
references.pmid: 17848748
references.citation: Apoptosis. 2008 Jun;13(6):782-9
references.pmid: 18437576
references.citation: J Cancer Res Ther. 2008 Apr-Jun;4(2):93-4
references.pmid: 18688127
references.citation: Mayo Clin Proc. 2008 Sep;83(9):1032-45
references.pmid: 18775204
references.citation: N Engl J Med. 2008 Nov 6;359(19):1995-2004
references.pmid: 18923165
references.citation: N Engl J Med. 2009 Jan 1;360(1):89-90
references.pmid: 19118315
references.citation: Hepatol Res. 2009 May;39(5):479-89
references.pmid: 19207585
references.citation: N Engl J Med. 2009 Feb 12;360(7):679-91
references.pmid: 19213681
references.citation: N Engl J Med. 2009 Apr 23;360(17):1789; author reply 1791-2
references.pmid: 19387022
references.citation: J Immunol. 2009 Jun 1;182(11):7287-96
references.pmid: 19454726
references.citation: Biochem Pharmacol. 2009 Jul 15;78(2):133-41
references.pmid: 19464430
references.citation: Int J Cancer. 2009 Oct 1;125(7):1705-9
references.pmid: 19521984
references.citation: Int J Cancer. 2010 Jan 1;126(1):90-103
references.pmid: 19569175
references.citation: Lancet Oncol. 2009 Sep;10(9):872-6
references.pmid: 19674936
references.citation: Cancer Chemother Pharmacol. 2010 May;65(6):1137-43
references.pmid: 19760218
references.citation: J Cell Mol Med. 2011 Mar;15(3):501-13
references.pmid: 20015195
references.citation: Br J Cancer. 2010 Mar 2;102(5):799-802
references.pmid: 20160722
references.citation: Dig Dis Sci. 2010 Dec;55(12):3404-7
references.pmid: 20397052
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2690-7
references.pmid: 20439627
references.citation: Ann Oncol. 2010 Nov;21(11):2188-94
references.pmid: 20444845
references.citation: Cancer Chemother Pharmacol. 2011 Mar;67(3):557-67
references.pmid: 20473610
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3577-81
references.pmid: 20567021
references.citation: Clin Cancer Res. 2010 Jul 1;16(13):3420-30
references.pmid: 20570927
references.citation: Cancer Immunol Immunother. 2010 Nov;59(11):1611-9
references.pmid: 20582413
references.citation: Bone. 2011 Jan;48(1):71-9
references.pmid: 20655399
references.citation: JAMA. 2010 Aug 11;304(6):657-63
references.pmid: 20699457
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: BMJ. 2010 Sep 01;341:c4444
references.pmid: 20813820
references.citation: Hepatol Res. 2010 Dec;40(12):1195-203
references.pmid: 21040275
references.citation: Ann N Y Acad Sci. 2010 Nov;1211:107-12
references.pmid: 21062299
references.citation: Lancet. 2010 Dec 11;376(9757):1989-99
references.pmid: 21131037
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1146-50
references.pmid: 21321296
references.citation: Drug Healthc Patient Saf. 2010;2:121-37
references.pmid: 21701624
references.citation: Anticancer Res. 2011 Jul;31(7):2419-24
references.pmid: 21873153
references.citation: Cancer Sci. 2012 Jan;103(1):58-66
references.pmid: 21954965
references.citation: Cancer Treat Rev. 2012 Aug;38(5):407-15
references.pmid: 21983264
references.citation: Int J Cancer. 2012 Sep 1;131(5):E717-25
references.pmid: 22161552
references.citation: Cancer Immunol Immunother. 2012 Sep;61(9):1373-85
references.pmid: 22215137
references.citation: Ann N Y Acad Sci. 2011 Dec;1240:E19-25
references.pmid: 22360293
references.citation: Osteoporos Int. 2012 Nov;23(11):2693-701
references.pmid: 22392160
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):993-5
references.pmid: 22490321
references.citation: Hepatology. 2013 Apr;57(4):1416-25
references.pmid: 22815256
references.citation: Osteoporos Int. 2013 Jan;24(1):279-86
references.pmid: 23052941
references.citation: Anticancer Res. 2012 Oct;32(10):4299-305
references.pmid: 23060550
references.citation: Liver Int. 2013 Jan;33(1):127-36
references.pmid: 23088518
references.citation: PLoS One. 2012;7(10):e47616
references.pmid: 23112825
references.citation: World J Gastroenterol. 2012 Oct 28;18(40):5779-88
references.pmid: 23155320
references.citation: Dis Esophagus. 2013 Aug;26(6):636-43
references.pmid: 23163484
references.citation: Clin Gastroenterol Hepatol. 2013 Mar;11(3):232-9.e1
references.pmid: 23220165
references.citation: BMJ. 2013 Jan 16;346:f114
references.pmid: 23325866
references.citation: Chin Med J (Engl). 2013;126(8):1486-90
references.pmid: 23595382
references.citation: Angiogenesis. 2013 Oct;16(4):809-20
references.pmid: 23716000
references.citation: Gan To Kagaku Ryoho. 2013 May;40(5):635-7
references.pmid: 23863589
references.citation: Pancreatology. 2013 Sep-Oct;13(5):508-16
references.pmid: 24075516
references.citation: J Cancer Ther. 2013 May;4(3):797-803
references.pmid: 24089656
references.citation: Transl Oncol. 2013 Oct 01;6(5):596-606
references.pmid: 24151540
references.citation: Acta Pharmacol Sin. 2013 Dec;34(12):1535-44
references.pmid: 24241351
references.citation: Int J Proteomics. 2014;2014:532953
references.pmid: 24653834
references.citation: Hepatology. 2014 Apr;59(4):1577-90
references.pmid: 24677197
references.citation: Eur J Cancer. 2014 Jul;50(10):1740-6
references.pmid: 24797764
references.citation: PLoS One. 2014 Jun 26;9(6):e101260
references.pmid: 24968029
references.citation: Br J Cancer. 2014 Sep 9;111(6):1139-49
references.pmid: 25025965
references.citation: Lancet Oncol. 2014 Aug;15(9):997-1006
references.pmid: 25035292
references.citation: J Gastroenterol Hepatol. 2015 Mar;30(3):619-27
references.pmid: 25167891
references.citation: Osteoporos Int. 2015 Feb;26(2):663-72
references.pmid: 25349053
references.citation: Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000
references.pmid: 25453078
references.citation: Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17989-94
references.pmid: 25453081
references.citation: Oncologist. 2015 Jan;20(1):7-12
references.pmid: 25480824
references.citation: Cancer Treat Rev. 2015 May;41(5):455-64
references.pmid: 25913713
references.citation: Ther Adv Chronic Dis. 2015 Jul;6(4):185-93
references.pmid: 26137208
references.citation: Ther Adv Musculoskelet Dis. 2015 Aug;7(4):160-8
references.pmid: 26288666
references.citation: Transl Gastrointest Cancer. 2013 Jul;2(3):130-144
references.pmid: 28989865
references.citation: N Engl J Med. 1996 Oct 3;335(14):1016-21
references.pmid: 8793925
references.citation: J Bone Miner Res. 1998 Apr;13(4):581-9
references.pmid: 9556058